XML 67 R52.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment and Geographical Data (Tables)
 12 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Business Segment
Selected information by business segment is as follows:

Fiscal Year

2016
 
2015
 
2014
Net sales:
 
 
 
 
 
Specialty Brands
$
2,300.6

 
$
1,622.8

 
$
413.5

Specialty Generics
1,025.2

 
1,251.6

 
1,199.4

Net sales of operating segments (1)
3,325.8

 
2,874.4

 
1,612.9

Other (2)
55.0

 
48.7

 
37.4

Net sales
$
3,380.8

 
$
2,923.1

 
$
1,650.3

Operating income:
 
 
 
 
 
Specialty Brands
$
1,166.2

 
$
637.6

 
$
(68.6
)
Specialty Generics
376.1

 
594.4

 
599.4

Segment operating income
1,542.3

 
1,232.0

 
530.8

Unallocated amounts:
 
 
 
 
 
Corporate and allocated expenses (3)          
(169.8
)
 
(282.6
)
 
(227.7
)
Intangible asset amortization
(700.1
)
 
(550.3
)
 
(154.8
)
Restructuring and related charges, net (4)
(38.2
)
 
(45.3
)
 
(68.2
)
Non-restructuring impairments
(16.9
)
 
—

 
(27.1
)
Separation costs
—

 
—

 
(9.6
)
Operating income
$
617.3

 
$
353.8

 
$
43.4

 
 
 
 
 
 
Depreciation and amortization (5):
 
 
 
 
 
Specialty Brands
$
716.6

 
$
559.5

 
$
153.3

Specialty Generics
96.8

 
81.6

 
78.2

 
$
813.4

 
$
641.1

 
$
231.5

(1)
Amounts represent sales to external customers. There were no intersegment sales.
(2)
Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.
(3)
Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
(4)
Includes restructuring-related accelerated depreciation.
(5)
Depreciation for certain shared facilities is allocated based on occupancy percentage.
Schedule of Net Sales from External Customers by Products
Net sales by product family within the Company's segments are as follows:
 
Fiscal Year
 
2016
 
2015
 
2014
Acthar
$
1,160.4

 
$
1,037.3

 
$
122.9

Inomax
474.3

 
185.2

 
—

Ofirmev
284.3

 
263.0

 
124.4

Therakos immunotherapy
207.6

 
—

 
—

Hemostasis products
42.5

 
—

 
—

Other
131.5

 
137.3

 
166.2

Specialty Brands
2,300.6

 
1,622.8

 
413.5

 
 
 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
146.5

 
167.2

 
99.4

Oxycodone (API) and oxycodone-containing tablets
126.2

 
154.6

 
155.2

Methylphenidate ER
103.5

 
136.5

 
209.6

Other controlled substances
468.1

 
572.2

 
584.5

Other
180.9

 
221.1

 
150.7

Specialty Generics
1,025.2

 
1,251.6

 
1,199.4

 
 
 
 
 
 
Other (1)
55.0

 
48.7

 
37.4

Net sales
$
3,380.8

 
$
2,923.1

 
$
1,650.3

(1)
Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.
Schedule of Net Sales and Long-Lived Assets by Geographical Area
Selected information by geographic area excluding assets held for sale is as follows:
 
Fiscal Year
 
2016
 
2015
 
2014
Net sales (1):
 
 
 
 
 
U.S.
$
3,095.4

 
$
2,647.0

 
$
1,485.0

Europe, Middle East and Africa
211.8

 
159.0

 
140.8

Other
73.6

 
117.1

 
24.5

 
$
3,380.8

 
$
2,923.1

 
$
1,650.3

Long-lived assets (2):
 
 
 
 
 
U.S.
$
742.4

 
$
747.8

 
 
Europe, Middle East and Africa (3)
61.2

 
13.4

 
 
Other
52.5

 
44.5

 
 
 
$
856.1

 
$
805.7

 
 
(1)
Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.
(2)
Long-lived assets are primarily composed of property, plant and equipment.
(3)
Includes long-lived assets located in Ireland of $59.3 million, and $10.7 million at the end of fiscal 2016 and 2015, respectively.